Trials / Completed
CompletedNCT04052594
A Study of LY3475766 in Healthy Participants
A Randomized, Double-Blind, Single Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3475766
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and tolerability of LY3475766 when given to participants with high levels of blood fat called triglycerides. It will also investigate how the body processes the study drug and the effect of the study drug on the body. Information about any side effects will be documented. This study will last up to 16 weeks for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3475766 - IV | Administered IV |
| DRUG | LY3475766 - SC | Administered SC |
| DRUG | Placebo - IV | Administered IV |
| DRUG | Placebo - SC | Administered SC |
Timeline
- Start date
- 2019-09-03
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
- First posted
- 2019-08-12
- Last updated
- 2021-04-28
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04052594. Inclusion in this directory is not an endorsement.